Qube Research & Technologies LTD Humanigen, Inc Transaction History

Qube Research & Technologies LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.15 - $3.02 $761 - $15,338	-5,079 Reduced 11.6%	38,691 $7,000
Q2 2022 Aug 15, 2022	BUY	$1.76 - $3.33 $77,035 - $145,754	43,770 New	43,770 $77,000
Q1 2022 May 09, 2022	SELL	$1.81 - $3.97 $445,989 - $978,219	-246,403 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$3.66 - $8.22 $901,834 - $2.03 Million	246,403 New	246,403 $917,000
Q3 2021 Nov 12, 2021	SELL	$5.93 - $17.83 $676,399 - $2.03 Million	-114,064 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$13.54 - $22.74 $1.33 Million - $2.23 Million	98,045 Added 612.05%	114,064 $1.98 Million
Q1 2021 May 14, 2021	SELL	$12.91 - $23.83 $815,705 - $1.51 Million	-63,184 Reduced 79.77%	16,019 $306,000
Q4 2020 Feb 16, 2021	BUY	$7.97 - $21.66 $631,247 - $1.72 Million	79,203 New	79,203 $1.39 Million

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.